Arcus Biosciences (RCUS)

Arcus Biosciences (RCUS) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.

RCUS edges higher as biotech investors weigh pipeline progress

Arcus Biosciences is up 1.0% today, broadly in step with a stronger market, but the shares remain under pressure after falling 10.5% over the past week. Traders are weighing its cancer-drug pipeline progress against a steep recent decline.

Published 2026-11-19 15:01:34 UTC.